Intellectual Property Universal and Master Agreements (UT Authentication Required)


Disclaimer: The materials on this website do not constitute legal advice. You should consult with an attorney before acting on or conveying any interpretation of these materials.
These agreements are available as starting points for negotiations with particular research sponsors for clinical and, in some cases, preclinical or other types of studies. Faculty members are welcomed to use these documents as starting points; however, all contracts must be processed through the appropriate office at each UT institution. 
Contact Marc Vockell or Sheila Kadura in OGC for copies of standard contracts specific to UT institutions.

Active Agreements

Abbott Laboratories

AbbVie Inc.

Alexion Pharmaceuticals, Inc.

Amgen, Inc. 

Army Research Laboratory (ARL)

Astellas Pharma US, Inc. / 
Astellas Pharma Global Development, Inc.

AstraZeneca Pharmaceuticals LP /
AstraZeneca LP/AstraZeneca Pharmaceuticals LP

BeiGene, USA, Inc.

BoehringerIngelheim Pharmaceuticals, Inc.

Bristol-Myers Squibb

Genentech, Inc.

Genzyme Corporation (see Sanofi)

Howmedica Stryker

Janssen Research & Development, LLC

Lilly USA, LLC

Merck Sharp & Dohme Corp. f/k/a 
Schering Corporation

Novartis Pharmaceuticals Corporation

Novo Nordisk, Inc.

Pfizer Inc.

Pharmacyclics LLC
(now owned by AbbVie Inc.)

Regeneron Pharmaceuticals, Inc.

Sanofi US Services Inc.

Statewide Institutional Review Boards (IRBs)

UCB Biosciences Inc. / UCB Biopharma SRL

UT System 


Terminated Agreements

BoehringerIngelheim Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.

Clinical Trials Xpress (CTX)

CytoSorbents Corporation

Genprex, Inc.

GlaxoSmithKline LLC (GSK)

PPD Investigator Services, LLC